Product Description
MT-4129 is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension
Mechanisms of Action: Aldosterone Synthase Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MT-4129-E01 | P1 |
Completed |
Healthy Volunteers |
2017-05-01 |